<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320085</url>
  </required_header>
  <id_info>
    <org_study_id>CMEK162X2201</org_study_id>
    <secondary_id>2010-023412-13</secondary_id>
    <nct_id>NCT01320085</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma</brief_title>
  <official_title>A Phase II, Open-label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults With Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600 or NRAS Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <brief_summary>
    <textblock>
      The study will assess the safety and efficacy of single-agent MEK162 in adult patients with
      locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring
      BRAFV600E or NRAS mutations.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">January 7, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) - Efficacy</measure>
    <time_frame>every 8 weeks up to end of study</time_frame>
    <description>The primary objective is to estimate the objective responses rate (ORRs) of MEK162 when administered orally as i. 45mg twice-daily, to adult patients with advanced, unresectable cutaneous malignant melanoma, harboring BRAFV600 or NRAS mutations and ii. 60mg twice-daily, to adult patients with advanced, unresectable cutaneous malignant melanoma, harboring BRAFV600 mutations. ORR is defined as the rate of best overall response (CR+PR), determined by RECIST.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free SUurvival (PFS)</measure>
    <time_frame>every 8 weeks up to end of study</time_frame>
    <description>The key secondary efficacy objective is estimation of progression free survival (PFS) distribution by study arm. PFS is defined as the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause, as per RECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival, Duration of response (DoR) and Time to Response</measure>
    <time_frame>every 8-12 weeks up to end of study</time_frame>
    <description>These endpoints will allow further analysis of the efficacy of MEK162</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events and changes in laboratory values</measure>
    <time_frame>every 30 days after last dose</time_frame>
    <description>To characterize safety and tolerability of MEK162</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pharmacodynamics pre- and post-dose</measure>
    <time_frame>After 15 days of dosing</time_frame>
    <description>To measure the changes in molecular markers of cell proliferation/survival pre-vs. post-dose tumor tissues and potential correlation with clinical outcomes</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>BRAF or NRAS Mutant Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>BRAFV600 mutant, 45mg bid MEK162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BRAFV600 mutant, 45mg bid MEK162</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRAS mutant, 45mg bid MEK162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NRAS mutant, 45mg bid MEK162</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BRAFV600 mutant, 60mg bid MEK162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BRAFV600 mutant, 60mg bid MEK162</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEK162</intervention_name>
    <arm_group_label>BRAFV600 mutant, 45mg bid MEK162</arm_group_label>
    <arm_group_label>NRAS mutant, 45mg bid MEK162</arm_group_label>
    <arm_group_label>BRAFV600 mutant, 60mg bid MEK162</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced or metastatic cutaneous melanoma AJCC Stage IIIB to IV, not
             potentially curable with surgery

          -  BRAF or NRAS mutation in tumor tissue

          -  All patients enrolled should provide sufficient fresh or archival tumor sample at
             baseline to enable confirmation of BRAF or NRAS mutations and the additional analyses
             described in the protocol

          -  Evidence of measurable tumor disease as per RECIST

          -  WHO performance status of 0-2

          -  Adequate organ function and laboratory parameters

        Exclusion Criteria:

          -  History or evidence of central serous retinopathy (CSR), retinal vein occlusion (RVO)
             or any eye condition that would be considered a risk factor for CSR or RVO

          -  Patients with unstable CNS metastasis

          -  Prior treatment with a MEK- inhibitor

          -  Impaired cardiovascular function

          -  HIV, active Hepatitis B, and/or active Hepatitis C infection

          -  Pregnant or nursing (lactating) women

          -  Women of child-bearing potential UNLESS they comply with protocol contraceptive
             requirements

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Array BioPharma</last_name>
    <role>Study Director</role>
    <affiliation>303-381-6604</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Highlands Oncology Group Dept of Highlands Oncology Grp</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute Moffitt 5</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University OHSU 2</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital and Health Network St. Luke's Cancer Network (2)</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas CCC Faris</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maastricht</city>
        <zip>5800</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <disposition_first_submitted>January 30, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>January 30, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 31, 2017</disposition_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic melanoma,</keyword>
  <keyword>BRAF-mutant,</keyword>
  <keyword>NRAS-mutant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

